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uib.noAbstractIn about 95% of cases, congenital adrenal hyperplasia (CAH) is caused by mutations in
CYP21A2 gene encoding steroid 21-hydroxylase (21OH). Recently, we have reported four
novel CYP21A2 variants in the Norwegian population of patients with CAH, of which
p.L388R and p.E140K were associated with salt wasting (SW), p.P45L with simple virilising
(SV) and p.V211MCp.V281L with SV to non-classical (NC) phenotypes. We aimed to
characterise the novel variants functionally utilising a newly designed in vitro assay of 21OH
enzyme activity and structural simulations and compare the results with clinical phenotypes.
CYP21A2 mutations and variants were expressed in vitro. Enzyme activity was assayed by
assessing the conversion of 17-hydroxyprogesterone to 11-deoxycortisol by liquid
chromatography tandem mass spectroscopy. PyMOL 1.3 was used for structural simulations,
and PolyPhen2 and PROVEAN for predicting the severity of the mutants. The CYP21A2
mutants, p.L388R and p.E140K, exhibited 1.1 and 11.3% of wt 21OH enzyme activity,
respectively, in vitro. We could not detect any functional deficiency of the p.P45L variant
in vitro; although prediction tools suggest p.P45L to be pathogenic. p.V211M displayed
enzyme activity equivalent to the wt in vitro, which was supported by in silico analyses.
We found good correlations between phenotype and the in vitro enzyme activities of the SW
mutants, but not for the SV p.P45L variant. p.V211M might have a synergistic effect together
with p.V281L, explaining a phenotype between SV and NC CAH.Key Words
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.0 UEndocrine Connections
(2014) 3, 67–74IntroductionThe CYP21A2 gene encodes the enzyme steroid
21-hydroxylase (21OH), which is essential for steroid
synthesis in the adrenal cortex. Mutations in CYP21A2
are the main cause of the autosomal recessive disorder
congenital adrenal hyperplasia (CAH) (1). The classical
forms of CAH are the salt wasting (SW) and simplevirilising (SV) phenotypes with adrenocorticotropic
hormone-driven excess of androgens leading to ambi-
guous genitalia in female newborns. The SW phenotype
has complete or almost complete loss of enzyme activity,
leading to lack of cortisol and aldosterone, whereas the
SV displays various degrees of reduced enzyme activitysed under a Creative Commons
nported License.
Table 1 Clinical description of the CAH patients with novel
variants in CYP21A2.
Variant Clinical phenotype
Age of
diagnoses Treatment
p.L388R Salt wasting Newborn Mineralo-
corticoidsClitoris hypertrophy
Glucocorticoids
p.E140K Salt wasting 1 week
old
Mineralo-
corticoids
Glucocorticoids
p.P45L Simple virilising 4 years Glucocorticoids
Clitoris hypertrophy
p.V211MC
p.V281L
Simple virilising/
non-classical CAH
21 years Glucocorticoids
Pubes growth and
pronounced
hirsutism from
7 years old
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2–8 3 :68resulting in cortisol insufficiency (1, 2). The non-classical
(NC) CAH is milder and characterised by signs of
hyperandrogenism postnatally and in adulthood, and
associated with minor mutations (3).
The most common mutations in the CYP21A2 gene are
derived from a non-functional pseudogene CYP21A1P (4).
Both CYP21A2 and CYP21A1P are located in the RCCX
module of the HLA class III locus of chromosome 6 and share
about 98% sequence homology. In general, there is a high
correlation between the CYP21A2 genotype and the CAH
phenotype (5, 6). In addition to the pseudogene mutations,
more than 160 other pathological variants of CYP21A2
have been reported (www.cypalleles.ki.se/cyp21.htm).
In the present study, we used a new in vitro assay of
21OH enzyme activity and molecular computer modelling
to predict the phenotypes of recently detected variants
(p.L388R p.E140K, p.P45L and p.V211M) in the Norwegian
population (7). We also checked a novel variant (p.A159T),
detected in Norwegian patients with autoimmune
Addison’s disease (AAD) and in control populations.Subjects and methods
Subjects
We detected four novel variants: p.L388R, p.E140K,
p.P45L and p.V211M, in a cohort of 59 patients diagnosed
with CAH (7). Four unrelated female patients, each had
one of the missense variants listed above, except the
subject with p.V211M who also had a coupled p.V281L
mutation on the same allele. All patients exhibited
a deletion in the other allele (7). Clinical characteristics
of the patients are listed in Table 1. The fifth variant,
p.A159T, was found in heterozygosity in three of 370
patients with AAD and in one out of 330 Norwegian
healthy subjects.Genetic analyses of CYP21A2
Protocols for sequencing and copy number analyses of the
CYP21A2 gene were described previously (7, 8, 9, 10, 11).Mutagenesis
Stratagene’s QuikChange II Site Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA, USA) was used to
introduce point mutations in the pcDNA2 plasmid
containing CYP21A2 cDNA (a kind gift from Prof. Holger
Luthman, Department of Molecular Medicine, Karolinska
Institute, Stockholm, Sweden (12)), corresponding to thehttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0032
 2014 The authors
Published by Bioscientifica Ltdnovel CYP21A2 variants (p.L388R, p.E140K, p.P45L,
p.V211M and p.A159T). Three control variants of
CYP21A2 were also generated: p.R102K (normal variant),
p.I172N (SV phenotype) and p.G291R (SW phenotype).
Primers used for mutagenesis are listed in Table 2. The
mutagenesis was carried out according to the manufac-
tures protocol, using 16 cycles with 5 min extension time.
The mutagenesis was verified with direct sequencing, and
plasmids from positive clones were purified by HiSpeed
Plasmid Maxi Kit (Qiagen).In vitro protein expression of 21OH mutants
Non-radioactive TNT Quick Coupled Transcription/Tran-
slation system (Promega) with Sp6 RNA polymerase was
used for in vitro protein expression. Expression of all the
21OH variants was verified by western blot using a primary
antibody against 21OH (c17, goat polyclonal IgG,
Santa Cruz Biotechnology) and alkaline phosphatase-
conjugated donkey anti-goat IgG secondary antibody
(Santa Cruz Biotechnology).Relative quantitation of 21OH from in vitro expression
ELISA plates (MaxiSorp, Nunc Thermo Scientific, Wal-
tham, MA, USA) were coated over night with 10 ml of the
in vitro expression product diluted in PBS, pH 7.4. Primary
antibody against 21OH (Santa Cruz Biotechnology),
together with the corresponding alkaline phosphatase-
conjugated secondary antibody (Sigma) and the FAST
pNPP detection system (Sigma), was used to determine the
relative amount of 21OH in the reaction products.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 2 Primers used in mutagenesis.
Mutations Sequences (5 0/3 0)
p.P45L F: CAGCCCGACCTCCTGATCTATCTGCTTGG
R: CCAAGCAGATAGATCAGGAGGTCGGGCTG
p.R102K F: CAAGCTGGTGTCTAAGAACTACCCGGAC
R: GTCCGGGTAGTTCTTAGACACCAGCTTG
p.E140K F: CATGGAGCCAGTGGTGAAACAGCTGACCCAG-
GAG
R: CTCCTGGGTCAGCTGTTTCACCACTGGCTCCATG
p.A159T F: GGCACCCCTGTGACCATTGAGGAGG
R: CCTCCTCAATGGTCACAGGGGTGCC
p.I172N F: CACCTGCAGCATCAACTGTTACCTCACC
R: GGTGAGGTAACAGTTGATGCTGCAGGTG
p.G291R F: CTGCAGTGGACCTCCTGATCAGGGGCACTGAGAC-
CACAGCAAAC
R: GTTTGCTGTGGTCTCAGTGCCCCTGATCAG-
GAGGTCCACTGCAG
p.L388R F: GTCATCATTCCGAACAGACAAGGCGCCCACCTG
R: CAGGTGGGCGCCTTGTCTGTTCGGAATGATGAC
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monitoring (SRM) against two signature peptides of 21OH
(p.85–98, LQEELDHELGPGASSSR and p.317–333, WAD-
FAGRPEPLTYK). Briefly, 5 ml of each version of 21OH
reaction products were taken out for quantitative
determination of 21OH. The lysates were purified on
SDS–PAGE gel, and the bands corresponding to the
molecular weight of wt 21OH (56 kDa) were cut out for
trypsin treatment. Stable isotope-labelled synthetic
peptides (N-terminal replacement of lysine (13C6,
15N2)
or arginine (13C6,
15N4) respectively) were added in
constant amount before purification, resulting in a mass
difference of 8 or 10 Da to the corresponding endogenous
peptide. A Q-Trap 5500 (AB SCIEX) connected to a Dionex
Ultimate NCR-3500RS LC system was used for the SRM
analyses. The SRM data were analysed using Skyline,
version 2.1 (https://skyline.gs.washington.edu/), and the
most abundant transition was used for quantification. The
SRM analyses were carried out using standard procedures
by the Proteomics Unit (PROBE) at the University of
Bergen. For quantitation, the amounts of 21OH constructs
were calculated relative to the amounts of the 21OH
wt protein.Enzyme activity assay
The activity of the different 21OH constructs was estimated
by quantitating 11-deoxycortisol (11DOC) using
17-hydroxyprogesterone (17OHP) as substrate. The
enzyme reactions were set up mainly as described
previously (13). Briefly, from each 21OH construct, 50 ml
of the in vitro expression product were mixed with 15 pmolhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0032
 2014 The authors
Published by Bioscientifica Ltdof recombinant human cytochrome P450 oxidoreductase
(CYPOR, Sigma–Aldrich) and 25 ml of 300 mM 17OHP (in
10% methanol) on ice. Pre-warmed reaction buffer (50 mM
potassium phosphate (pH 7.4), 20% (v/v) glycerol, 2 mM
dithiothreitol, 0.1 mM EDTA and 0.0034% (v/v) Emulgen
913 (Karlan Research Products Corporation, Cottonwood,
AZ, USA)) was then added to a total volume of 500 ml. After
60 s of pre-incubation at 37 8C, the enzymatic reaction was
initiated by adding 5 ml of 100 mM NAPDH. The enzymatic
reaction was carried out for 1 h at 37 8C, and then
terminated by putting onto ice. Further, the enzyme
reaction solution was diluted 1:10 or 1:100 in a solution
of 50% methanol and 0.1% formic acid in double-distilled
(dd) H2O (v/v). An internal standard (IS) solution (50 nM
17OHP-d8 and 50 nM 11DOC-d2 in methanol) was then
added to the diluted samples in a 1:1 ratio. Working
standards of 11DOC in the range of 0.61–150 nM were
prepared by diluting stock solutions in a solution of 50%
methanol and 0.1% formic acid in ddH2O (v/v) and adding
IS (1:1). Working standards and 11DOC produced from
each enzymatic reaction were quantified by liquid
chromatography coupled to tandem mass spectroscopy
(LC–MSMS) (14). The enzyme activity was calculated as the
% ratio of 11DOC production between the 21OH mutants
to the wt, adjusted for the quantity of 21OH wt and mutant
in the enzymatic reactions.Structural simulations and in silico analyses
The molecular graphic images were generated from a
humanised version of bovine 21OH as template (15),
kindly provided from Dr Shozeb Haider (Centre of Cancer
Research and Cell Biology, Queens’s University of Belfast,
Belfast, UK), using The PyMOL Molecular Graphics
System, version 1.3 (Schro¨dinger, LLC, Portland, OR,
USA). Variants were modelled using the Mutagenesis tool
in PyMOL and distances between molecules measured
using the Measurement tool. The severity of the variants
was predicted by PolyPhen-2 v2.2.2r398 HumVar model
(http://genetics.bwh.harvard.edu/pph2/) (16) and PRO-
VEAN (http://provean.jcvi.org/index.php) (17) using
default settings. Sequence alignments of 21OH from
seven different species (GenBank: AAB59440.1 (Homo
sapiens), AAA30487.1 (Bos taurus), ABC69211.1 (Felis
catus), AAD05573.1 (Rattus norvegicus) and BAF63009.1
(Gallus gallus); NCBI reference sequence: XP_003311237.1
(Pan troglodytes) and NP_999598.1 (Sus scrofa)) were carried
out by default settings using Clustal omega (http://www.
ebi.ac.uk/Tools/msa/clustalo/) (18) in order to assess the
evolutionary conservation of the mutated amino acids.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Statistical analyses were performed by the GraphPad Prism,
version 5.02 Software (La Jolla, CA, USA). Correlations
between the ELISA and SRM methods for quantifying the
21OH proteins produced were calculated by Pearson’s
correlation test. Deviation of enzyme activity of the 21OH
mutants compared with the wt 21OH was calculated by
ANOVA combined with Dunnett’s multiple comparison
tests using a significance level of P!0.05.Results
Verification and relative quantitation of 21OH by
ELISA and SRM methods
Western blot analysis of the samples from in vitro expression
showed a 56-kDa band corresponding to the molecular
weight of 21OH for all constructs (data not shown).
The ELISA method for quantitation of the mutated
21OH proteins correlated very well with the SRM method
(P!0.0001, Pearson’s rZ0.9206, and 95% CI (0.8016,
0.9695), nZ19). Thus, the ELISA method was used for
further quantitation of 21OH.In vitro 21OH activity studies
The assay showed no significant reduction in the enzyme
activity of the p.R102K normal variant relative to the wt
(119.7%), whereas the p.I172N (SV phenotype) and
p.G291R (SW phenotype) mutations showed significant
(P!0.05) decline (1.6 and 0%, respectively, relative to wt
(Table 3)). The novel CAH mutations, p.L388R and
p.E140K, displayed significantly (P!0.05) reduced activityTable 3 Enzyme activity (% of WT) from four to five different e
variants.
Mutant/variant
% Average enzyme
activity (S.D.) Phenotype
p.K102R 119.7 (22.5) Normal
p.A159T 126.6 (29.9) Unknown
p.V211M 99.5 (32.4) SV/NCb
p.I172N 1.6 (0.8) SV
p.P45L 105.0 (10.6) SV
p.G291R 0c SW
p.E140K 11.3 (2.4) SW
p.L388R 1.1 (0.6) SW
NC, non-classical CAH; SV, simple virilising; SW, salt wasting.
aThreshold as deleterious set to !O2.5.
bPhenotype of p.V211MCp.V281L/deletion genotype.
cProduction of 11DOC concentration under the detection limit of LC–MSMS me
http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0032
 2014 The authors
Published by Bioscientifica Ltdof 1.1 and 11.3% compared with wt respectively (Table 3).
The other two novel CAH variants, p.P45L and p.V211M,
were similar to the wt (105 and 99.5% respectively) as was
p.A159T (126.6%) (Table 3).Structural simulations
The structures of 21OH and the novel variants based on the
humanised model (15) are illustrated in Fig. 1. For p.L388R,
the shift from the hydrophobic leucine to a negatively
charged arginine in position 388 will probably lead to a
disruption in a hydrophobic pocket surrounding the heme
group (Fig. 1a). This is a highly conserved region (Fig. 2), and
the p.L388R mutation was predicted as pathologic (Table 3).
The p.E140 residue forms a salt bridge with the R444
residue, and the shift from negatively charged glutamic
acid to positively charged lysine breaks the salt bridge
(Fig. 1b). A negatively charged amino acid in this residue is
highly conserved (Fig. 2); however, PolyPhen2 predicted
this mutation as possible damaging, while PROVEAN
predicted it as neutral (Table 3) in line with significant
residual enzyme activity (see above).
p.P45 is located early in the A helix (Fig. 1c), which is a
highly conserved region (Fig. 2). The proline-to-leucine
shift in position 45 was predicted as pathologic by both
PolyPhen2 and PROVEAN (Table 3), but in vitro enzyme
activity was normal.
The p.V211 residue (Fig. 1d) may interact with L65
through hydrophobic interactions and is located in a
semiconservative region (Fig. 2). The shift from valine to
methionine was predicted as benign/neutral (Table 3) in
line with normal enzyme activity.
The variant p.A159T (Fig. 1e) is located on the surface
of the 21OH protein. Sequence alignment shows that thexperiments and in silico prediction of CYP21A2 mutations and
Predicted phenotype (score)
PolyPhen2 PROVEANa
Benign (0.001) Neutral (0.722)
Benign (0.023) Neutral (0.36)
Benign (0.029) Neutral (O1.019)
Probably damaging (0.998) Deleterious (O5.499)
Probably damaging (1.0) Deleterious (O5.067)
Probably damaging (1.0) Deleterious (O4.637)
Possibly damaging (0.49) Neutral (O1.208)
Probably damaging (0.986) Deleterious (O4.995)
thod.
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 1
Tertiary structure of 21-hydoxylase with positions of five novel variants
generated by PyMOL v.3.1. (a) p.L388R, (b) p.E140K, (c) p.P45L, (d) p.V211M
and (e) p.A159T.
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Published by Bioscientifica Ltdalanine-to-threonine shift in position 159 is equal to the
sequences of B. taurus and S. scrofa 21OH (Fig. 2), and was
predicted as harmless (Table 3), again in line with a normal
enzyme activity.Discussion
In the present study, we introduced a novel method for
functional studies of CYP21A2 mutants. Using the
coupled transcription/translation system for protein
expression, we were able to measure the 21OH enzyme
activity without the need of cell culture facilities and
radiolabelling substrates, which is the current standard
method (19, 20, 21, 22). We then characterised five novel
and three known variants of the CYP21A2 gene found in
patients with CAH (7) and AAD. Overall, the measured
enzyme activities and structural simulation corresponded
to the phenotype with some exceptions.
The three polymorphisms used for verification of the
in vitro enzyme assay behaved as expected; p.R102K (23)
showed no reduction in activity, whereas the well-known
SV mutation p.I172N had !2% activity and the G291R
showed no activity at all, in accordance with previously
reports (24, 25, 26). The novel p.L388R mutation showed
almost complete abolishment of enzyme activity in vitro,
which is in total agreement with the SW phenotype and
the structural simulation. p.L388 is a crucial residue as it
interacts with the heme prosthetic group through hydro-
phobic interactions. When the leucine at this position
is replaced by the positively charged and more space-
demanding arginine, the heme group is restricted from its
normal binding to 21OH, which would have deleterious
consequences for the enzymatic activity as well as the
three-dimensional folding of 21OH.
The patient with the p.E140K mutation was diagnosed
as SW, but even if in vitro enzyme assay showed a
significant reduction in 21OH activity (11%), it was still
much higher than expected for the SW phenotype. In
addition, the prediction tools did not foresee a severe
damaging effect, and was more in line with a NC
phenotype. However, structural analysis shows that the
p.E140K disrupts a salt bridge with p.R444, which is crucial
for maintaining the tertiary structure (15) that could
explain the SW phenotype. Thus, prediction tools alone
are not always pre´cis (27). On the other hand, phenotype
and genotype divergence in classical CAH has been
described, and the same mutation can give different
phenotypes even in siblings (28).
The variant p.P45L was detected in a SV patient, but the
in vitro enzyme activity did not correlate to such a severeThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Figure 2
Amino acid sequence alignments of 21-hydroxylase for the p.P45, p.E140, p.A159, p.V211 and p.L388 residues for seven species.
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damaging/deleterious by computer modelling. The p.P45L
residue is located in the N-terminal region of the enzyme
close to the hydrophobic domain that anchors 21OH to the
endoplasmic reticulum (ER) membrane (15). The import-
ance of the far N-terminal region has been experimentally
determined earlier with regards to membrane targeting and
insertion, as well as in vivo protein stability (29). It has also
been demonstrated that the first 20 amino acids are
necessary for membrane integration but that enzymatic
activity in vitro can still be retained when these residues are
deleted (30). Moreover, the p.P45 residue marks the start of
an alpha helix that bends the direction of the polypeptide
chain back towards the membrane. It is possible that this
bending, for which proline in the 45 position is mandatory,
is crucial for the correct orientation of 21OH in the ER
membrane. If p.P45 is replaced by another amino acid, the
overall stability and in vivo enzymatic activity of the protein
may be severely decreased. Another possibility is that the
removal of the proline residue at position 45 alters the
enzymes orientation to the ER membrane and somehow
disturbs the electron transfer mediated in vivo by the
membrane-bound CYPOR. As we added exogenous CYPOR
in our in vitro assay, this effect could be lost. However, it is
still possible that the rest of the enzyme maintains its
structural integrity and that the intrinsic enzymatic
function is intact. Similar effects of mutated proline residues
have been described for other proteins, such as cubilin (the
intrinsic factor-B12 receptor) or the guanylate cyclase-
activating protein 1 (involved in central vision) (31, 32).
As we have carried out the functional characterisation of the
p.P45L mutant in the absence of membranes, the severely
reduced in vivo activity relative to wt 21OH could be missed
in our system. We therefore propose that future studies
shouldcompare our novel methodusing cell-freeexpression
of 21OH with the traditional use of transiently transfected
COS7 cells, preferably with LC–MSMS-based quantification
of steroids. In addition to the p.P45L mutant, such ahttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0032
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Published by Bioscientifica Ltdcomparative study should include a wide range of known
and well-characterised 21OH mutations and variants.
The patient with the p.V211M variant was classified
with a phenotype between SV and NC CAH. She also carried
the NC CAH mutation p.V281L on the same allele, whereas
the second allele was deleted. The in vitro 21OH activity of
p.V211M was similar to the wt; thus the cause of the
disorder might be from the p.V281L mutation, which
actually has been reported with SV phenotype (6). An
almost similar mutation, p.V211L, has been described
previously in a patient with NC CAH together with
p.V281L, and was suggested as normal based on no
conservation between four mammalian species (33).
Structural analysis shows that p.V211 is a part of the
substrate cavity site and that it probably interacts with L65
through hydrophobic interactions (15). The conversion of
valine into methionine at this position may alter this
interaction slightly, but probably not to a damaging degree.
PolyPhen2 and PROVEAN predicted p.V211M as benign/
neutral, but with a score close to the threshold. It is unclear
whether this mutation contributes to the intermediate form
of SV/NC CAH due to a synergistic effect, similarly that has
been seen in other studies were mild NC variants together
have given SV (20, 21, 22, 34, 35) or SW phenotypes (36).
Finally, the p.A159T variant showed no reduction in
the enzyme activity in vitro. This variant was found in
heterozygosity in three patients with AAD and in one
healthy subject, and was predicted as harmless. The
p.A159 residue is located on the surface of the protein in
a region outside the secondary structure motifs and away
from the active site, and occurs naturally in other
mammals such as pigs and cows (Fig. 2). The substitution
of alanine with threonine is also common in homologous
proteins from related species.
In conclusion, the in vitro enzyme assay and structural
simulations revealed good correlations to the most severe
phenotypes. For the other variants, a heterogeneous
picture was observed. Nevertheless, in vitro enzyme assaysThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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7–8 3 :73and structural simulations are valuable supplements for
evaluating the severity of novel CYP21A2 variants.Declaration of interest
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